Karyopharm Therapeutics (NASDAQ:KPTI) Earns “Outperform” Rating from Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “outperform” rating restated by research analysts at Royal Bank of Canada in a research report issued on Thursday,Benzinga reports. They presently have a $3.00 price target on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 401.34% from the company’s current price.

A number of other analysts also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Trading Down 1.9 %

Shares of NASDAQ KPTI opened at $0.60 on Thursday. The company has a 50 day simple moving average of $0.66 and a two-hundred day simple moving average of $0.76. The stock has a market cap of $75.51 million, a price-to-earnings ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 12 month low of $0.53 and a 12 month high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. Analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KPTI. Geode Capital Management LLC increased its holdings in Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after acquiring an additional 43,856 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. FMR LLC increased its stake in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after purchasing an additional 76,510 shares in the last quarter. Jane Street Group LLC raised its position in shares of Karyopharm Therapeutics by 265.5% during the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after purchasing an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at about $31,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).